Elsevier, Drug Discovery Today, Volume 22, 1 February 2017
Anti-infective drugs have had a key role in the contemporary world, contributing to dramatically decrease mortality rates caused by infectious diseases worldwide. Antimicrobial peptides (AMPs) are multifunctional effectors of the innate immune system of mucosal surfaces and present antimicrobial activity against a range of pathogenic viruses, bacteria, and fungi. However, the discovery and development of new antibacterial drugs is a crucial step to overcome the great challenge posed by the emergence of antibiotic resistance. In this review, we outline recent advances in the development of novel AMPs with improved antimicrobial activities that were achieved through characteristic structural design. In addition, we describe recent progress made to overcome some of the major limitations that have hindered peptide biosynthesis.
Animal; Animals; Anti-Bacterial Agents; Antibacterial Activity; Antibiotic Resistance; Antibiotic Therapy; Antiinfective Agent; Bacterial Infection; Biosynthesis; CRISPR Cas System; CRISPR-Cas Systems; Chemical Modification; Chemistry; Clustered Regularly Interspaced Short Palindromic Repeat; Drug Design; Drug Mechanism; Drug Metabolism; Drug Resistance, Bacterial; Drug Resistance, Multiple; Drug Therapy; Economics; Gene Editing; Human; Humans; Medical Technology; Metabolism; Multidrug Resistance; New Drug; Nonhuman; Peptide; Peptide Biosynthesis; Peptide Synthesis; Peptides; Phase 1 Clinical Trial (topic); Phase 2 Clinical Trial (topic); Phase 3 Clinical Trial (topic); Polypeptide Antibiotic Agent; Review; Social Change; Tobacco; Global